✦ LIBER ✦

Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX-67), a Non-Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

✍ Scribed by K. Komoriya; S. Hoshide; K. Takeda; H. Kobayashi; J. Kubo; M. Tsuchimoto; T. Nakachi; H. Yamanaka; N. Kamatani

Publisher: John Wiley and Sons
Year: 2005
Weight: 9 KB
Volume: 36
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200509209

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Febuxostat (TMX-67), a Novel, Non-Purine

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

✍ M. A. Becker; J. Kisicki; R. Khosravan; J. Wu; D. Mulford; B. Hunt; P. MacDonald 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 8 KB

## Abstract For Abstract see ChemInform Abstract in Full Text.

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal